Login / Signup

New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Ermina StratinaCarol StanciuRobert NastasaSebastian ZenoviaRemus StafieAdrian RotaruTudor CuciureanuCristina Maria MuzicaCatalin Victor SfartiIrina GîrleanuHoria MineaOana Cristina PetreaLaura HuibanStefan ChiriacAna-Maria SingeapOana VladCamelia CojocariuAnca Victorița Trifan
Published in: Diagnostics (Basel, Switzerland) (2024)
The superior metabolic effects of semaglutide, correlated to dapagliflozin, may contribute to a more efficient decrease in hepatic stress and injury, leading to a substantial enhancement of liver function in T2DM patients. Further investigations conducted over an ideal timeframe are necessary to confirm the evidence presented in this study.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • oxidative stress
  • type diabetes
  • metabolic syndrome
  • heat stress
  • patient reported